Hydroxychloroquine Market: Information by Type (USP Standard Grade, EP Standards Grade), Applications (Rheumatoid Arthritis, Malaria, COVID 19) , and Region — Forecast till 2029

May 27, 2020   Market Overview The hydroxychloroquine market was valued at USD 545.6 million in 2019 and is projected to grow with a CAGR of 32.8%.   Hydroxychloroquine, also referred to as hydroxychloroquine sulfate, possesses an immunosuppressive action with anti-viral characteristics. It is primarily prescribed for the treatment of infectious diseases such as malaria and auto-immune diseases such as lupus and rheumatoid arthritis. Rising prevalence of such diseases, especially in Africa and Southeas...
Request Free Sample Report

Table Of Content

TABLE OF CONTENTS

1          Introduction

1.1       Market Definition

1.2       Market Scope

2          Research Methodology

2.1       Primary Research

2.2       Research Methodology

2.3       Assumptions & Exclusions

2.4       Secondary Data Applications

3          Market Overview

3.1       Report Segmentation & Scope

3.2       Value Chain Analysis:  Hydroxychloroquine Market

3.3       Key Market Trends

3.3.1   Drivers

3.3.2   The Restraints

3.3.3   Opportunities

3.4       Porter’s Five Forces Analysis

3.4.1   Bargaining Power of Suppliers

3.4.2   Bargaining Power of Buyers

3.4.3   Threat of Substitution

3.4.4   Threat of New Entrants

3.4.5   Competitive Rivalry

3.5       Market Share Analysis

3.6       Top wining strategies

3.7       Top investment pockets

3.8       Impact of COVID 19

3.9       Production Analysis

3.10    Demand-Supply Analysis

4          Type Overview

4.1       Introduction

4.1.1   Market Size & Forecast (Value)

4.2       USP Standards Grade

4.2.1   Market Size & Forecast (Value)

4.3       Pharmaceutical Standards Grade

4.3.1   Market Size & Forecast (Value)

4.4       EP Standards Grade

4.4.1   Market Size & Forecast (Value)

4.5       Others

4.5.1   Market Size & Forecast (Value

5          Applications Overview

5.1       Introduction

5.1.1   Market Size & Forecast (Value)

5.2       Rheumatoid Arthritis

5.2.1   Market Size & Forecast (Value)

5.3       Malaria

5.3.1   Market Size & Forecast (Value)

5.4       Systemic Lupus Erythematosus

5.4.1   Market Size & Forecast (Value)

5.5       COVID 19

5.5.1   Market Size & Forecast (Value)

5.6       Other

5.6.1   Market Size & Forecast (Value)

6          Regional Overview

6.1      Introduction

6.1.1   Market Size & Forecast (Value)

6.2      North America

6.2.1   North America

6.2.1.1      The U.S.

6.2.1.1.1         By Type

6.2.1.1.2         By Applications

6.2.1.2      Canada

6.2.1.2.1         By Type

6.2.1.2.2         By Applications

6.2.1.3      Mexico

6.2.1.3.1         By Type

6.2.1.3.2         By Applications

6.2.2   Central and South America and the Caribbean

6.2.2.1      By Type

6.2.2.2      By Applications

6.2.2.2.1   Brazil

6.2.2.2.1.1      By Type

6.2.2.2.1.2      By Applications

6.2.2.2.2   Argentina

6.2.2.2.2.1      By Type

6.2.2.2.2.2      By Applications

6.2.2.2.3   The Rest of Central and South America and the Caribbean

6.2.2.2.3.1      By Type

6.2.2.2.3.2      By Applications

6.3      Europe

6.3.1   Market Size & Forecast (Value)

6.3.2   Western Europe

6.3.2.1      The U.K.

6.3.2.1.1         By Type

6.3.2.1.2         By Applications

6.3.2.2      Germany

6.3.2.2.1         By Type

6.3.2.2.2         By Applications

6.3.2.3      France

6.3.2.3.1         By Type

6.3.2.3.2         By Applications

6.3.2.4      Spain

6.3.2.4.1         By Type

6.3.2.4.2         By Applications

6.3.2.5      Italy

6.3.2.5.1         By Type

6.3.2.5.2         By Applications

6.3.2.6      The Rest of Western Europe

6.3.2.6.1         By Type

6.3.2.6.2         By Applications

6.3.3   Eastern Europe

6.3.3.1             By Type

6.3.3.2             By Applications

6.3.4   The Rest of Europe

6.3.4.1             By Type

6.3.4.2             By Applications

 

6.4      Asia-Pacific

6.4.1   Market Size & Forecast (Value)

6.4.2   Japan

6.4.2.1            By Type

6.4.2.2            By Applications

6.4.3   China

6.4.3.1            By Type

6.4.3.2            By Applications

6.4.4   Australia

6.4.4.1            By Type

6.4.4.2            By Applications

6.4.5   India

6.4.5.1            By Type

6.4.5.2            By Applications

6.4.6   South Korea

6.4.6.1            By Type

6.4.6.2            By Applications

6.4.7   The Rest of Asia-Pacific

6.4.7.1            By Type

6.4.7.2            By Applications

6.5      The Middle East & Africa

6.5.1   The Middle East

6.5.1.1            Market Size & Forecast (Value)

6.5.1.2            Saudi Arabia

6.5.1.2.1         By Type

6.5.1.2.2         By Applications

6.5.1.3            The UAE

6.5.1.3.1         By Type

6.5.1.3.2         By Applications

6.5.1.4            Qatar

6.5.1.4.1         By Type

6.5.1.4.2         By Applications

6.5.2   The Africa

6.5.2.1            Market Size & Forecast (Value)

7          Company Profile

7.1      Mylan N.V.

7.1.1   Company Overview

7.1.2   Financial Performance

7.1.3   Recent Developments

7.1.4   Type Portfolio

7.2      Teva Pharmaceutical Industries Ltd.

7.2.1   Company Overview

7.2.2   Financial Performance

7.2.3   Recent Developments

7.2.4   Type Portfolio

7.3      Sanofi S.A.

7.3.1   Company Overview

7.3.2   Financial Performance

7.3.3   Recent Developments

7.3.4   Type Portfolio

7.4      IPCA Laboratories

7.4.1   Company Overview

7.4.2   Financial Performance

7.4.3   Recent Developments

7.4.4   Type Portfolio

7.5      Hikma Pharmaceuticals Plc

7.5.1   Company Overview

7.5.2   Financial Performance

7.5.3   Recent Developments

7.5.4   Type Portfolio

7.6      Shanghai Pharmaceutical Group Co.

7.6.1   Company Overview

7.6.2   Financial Performance

7.6.3   Recent Developments

7.6.4   Type Portfolio

7.7      Jiangsu Shenhua Pharmaceutical Co., Ltd.

7.7.1   Company Overview

7.7.2   Financial Performance

7.7.3   Recent Developments

7.7.4   Type Portfolio

7.8      Taj Pharmaceuticals Limited 

7.8.1   Company Overview

7.8.2   Financial Performance

7.8.3   Recent Developments

7.8.4   Type Portfolio

7.9      Cinkate Corporation

7.9.1   Company Overview

7.9.2   Financial Performance

7.9.3   Recent Developments

7.9.4   Type Portfolio  

8               Conclusion & Recommendations

9               Acronyms & Abbreviations